Case Overview

The Parties

The Patents at Issue

The dispute originally covered six patents. By trial, two remained active, both assigned to the Chang patent family covering controlled-release doxycycline formulations. These patents are crucial for protecting pharmaceutical innovations through the U.S. Patent and Trademark Office (USPTO).

• • US7,749,532 — Claims 1 and 16 asserted; directed to doxycycline formulations achieving therapeutic effects through controlled-release mechanisms.
• • US8,206,740 — Claims 1 and 20 asserted; covering related formulation and pharmacokinetic parameters.

Litigation Timeline & Procedural History

Galderma filed suit on December 3, 2021, invoking the standard 30-month stay mechanism under Hatch-Waxman. Delaware was the expected venue given its status as the premier forum for pharmaceutical patent litigation, offering experienced judges and well-developed Hatch-Waxman procedural norms.

The case proceeded through 850 days of litigation — roughly 28 months — before reaching resolution. A significant procedural development occurred on May 10–11, 2023, when parties entered a stipulation dismissing all claims related to four of the six originally asserted patents (**’405, ‘406, ‘364, and ‘478**) without prejudice. This narrowing of issues is common in complex ANDA litigation as parties refine their strongest positions ahead of trial.

Trial was held January 9–11, 2024 — a three-day bench trial before Judge Stephanos Bibas, a Third Circuit appointee known for rigorous analytical opinions. The court issued its Memorandum Opinion on March 22, 2024, with final judgment entered April 1, 2024.

Notably, the court retained jurisdiction over potential injunctive relief motions under FRCP 62(d) and 35 U.S.C. § 283, and stayed attorney fee motions pending any appeal outcome — preserving the litigation posture for potential post-judgment proceedings.

📎 Case documents available via PACER under Case No. 1:21-cv-01710 (D. Del.)

The Verdict & Legal Analysis

Outcome

The court entered final judgment for Lupin and against Galderma on all remaining claims. Specifically, the court found that Lupin’s ANDA product:

• Has not infringed, does not infringe, and would not infringe (if marketed) claims 1 and 16 of the ‘532 patent.
• Has not infringed, does not infringe, and would not infringe claims 1 and 20 of the ‘740 patent.

This finding encompassed both literal infringement and infringement under the doctrine of equivalents. All remaining infringement claims not expressly addressed were dismissed with prejudice. No damages were awarded. Injunctive relief was not granted at the judgment stage.

Verdict Cause Analysis

The court’s March 22, 2024 Memorandum Opinion — the analytical core of this decision — expressly stated that “Galderma has not proven that Lupin’s ANDA product infringes claims 1 and 16 of the Chang ‘532 patent” or “claims 1 and 20 of the Chang ‘740 patent.”

The structure of the verdict suggests that claim scope interpretation played a decisive role. In Hatch-Waxman infringement cases involving formulation patents, the critical battleground is typically whether the accused ANDA product’s formulation parameters fall within the literal scope of the claims — or, where they do not, whether differences are insubstantial enough to trigger the doctrine of equivalents.

Lupin’s defense successfully demonstrated that its formulation did not meet one or more limitations of the asserted claims. The court’s rejection of equivalents arguments further signals that Lupin achieved meaningful differentiation in its formulation design — a hallmark of successful ANDA design-around strategy.

Legal Significance

This ruling reinforces several important principles in pharmaceutical patent litigation:

1. Doctrine of equivalents remains difficult to establish in Hatch-Waxman cases where ANDA filers can demonstrate deliberate formulation differentiation.
2. Claim scope in formulation patents must be precisely drafted to cover meaningful ranges — overly narrow claims may not reach generic alternatives.
3. Bench trials in Delaware continue to produce highly analytical, claim-focused opinions that can serve as persuasive authority in parallel proceedings.